within Pharmacolibrary.Drugs.ATC.P;

model P01BE01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.21,
    Cl             = 0.04666666666666666,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.0014399999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Artemisinin is a sesquiterpene lactone isolated from the plant Artemisia annua, used primarily as an antimalarial agent. It is effective against Plasmodium falciparum malaria and is used in combination therapies for treatment. Artemisinin and its derivatives are widely used and recommended by the World Health Organization (WHO) for malaria treatment.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral dosing.</p><h4>References</h4><ol><li><p>Fu, C, et al., &amp; Qiu, F (2021). Oral Bioavailability Comparison of Artemisinin, Deoxyartemisinin, and 10-Deoxoartemisinin Based on Computer Simulations and Pharmacokinetics in Rats. <i>ACS omega</i> 6(1) 889–899. DOI:<a href=&quot;https://doi.org/10.1021/acsomega.0c05465&quot;>10.1021/acsomega.0c05465</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33458540/&quot;>https://pubmed.ncbi.nlm.nih.gov/33458540</a></p></li><li><p>Weathers, PJ, et al., &amp; Rich, SM (2014). Pharmacokinetics of artemisinin delivered by oral consumption of Artemisia annua dried leaves in healthy vs. Plasmodium chabaudi-infected mice. <i>Journal of ethnopharmacology</i> 153(3) 732–736. DOI:<a href=&quot;https://doi.org/10.1016/j.jep.2014.03.037&quot;>10.1016/j.jep.2014.03.037</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24661969/&quot;>https://pubmed.ncbi.nlm.nih.gov/24661969</a></p></li><li><p>Navaratnam, V, et al., &amp; Olliaro, P (2000). Pharmacokinetics of artemisinin-type compounds. <i>Clinical pharmacokinetics</i> 39(4) 255–270. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200039040-00002&quot;>10.2165/00003088-200039040-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11069212/&quot;>https://pubmed.ncbi.nlm.nih.gov/11069212</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end P01BE01;
